# Linagliptin Inpatient Trial

> **NCT02004366** · PHASE4 · COMPLETED · sponsor: **Emory University** · enrollment: 295 (actual)

## Conditions studied

- Type 2 Diabetes

## Interventions

- **DRUG:** Linagliptin
- **DRUG:** Basal Bolus
- **DRUG:** Linagliptin
- **DRUG:** Linagliptin + 50% Glargine dose on discharge
- **DRUG:** Linagliptin + 80% Glargine

## Key facts

- **NCT ID:** NCT02004366
- **Lead sponsor:** Emory University
- **Sponsor class:** OTHER
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-01
- **Primary completion:** 2017-02
- **Final completion:** 2017-03
- **Target enrollment:** 295 (ACTUAL)
- **Last updated:** 2019-02-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02004366

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02004366, "Linagliptin Inpatient Trial". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT02004366. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*